NovaBay Pharmaceuticals Launches Avenova® Eye Health Support, a New Antioxidant-Rich Oral Supplement to Comfort Dry Eyes and Promote Overall Eye Health
March 07 2023 - 6:50AM
Business Wire
Avenova Eye Health Support expands the Avenova
dry eye product line with a differentiated product combining
high-quality, concentrated omega-3 oils with the unique
nutrient-rich antioxidant maqui berry
NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces
the launch of OTC Avenova Eye Health Support oral supplement
featuring a combination of MaquiBright®, a nutrient-rich,
antioxidant-dense extract of the superfruit maqui berry, and high
quality, natural triglyceride omega-3 oils to comfort dry eyes and
support overall eye health.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20230307005090/en/
Avenova Eye Health Support Oral
Supplement with MaquiBright® (Photo: Business Wire)
Avenova Eye Health Support is sold as 60 easy-to-swallow softgel
capsules (30-day supply) and is available at Amazon.com and
Avenova.com for $41.95, and through optometrist offices
participating in NovaBay’s physician-dispensed channel.
“Our eyes are under more stress than ever with increasing
computer screen time, air pollution and indoor heating and cooling,
all of which can lead to dry eye and eye fatigue. In fact, up to 49
million Americans suffer from dry eyes and the global market for
dry eye products is expected to grow at 5% annually, reaching
nearly $9 billion by 2030,” said Justin Hall, NovaBay CEO. “We’re
excited to offer a unique eye health supplement that has the potent
maqui berry extract, which has three-times the antioxidant level of
blueberries and is found only in the forests of Patagonia. This
product is unique in the marketplace and the clinical effects of
the maqui berry extract are impressive.”
Participants in a four-week, randomized, double-blind,
placebo-controlled study on the effects of MaquiBright® extract
showed an 89% increase in tear production and reported a 57%
improvement in dry eye discomfort with Avenova Eye Health Support.
Study results were published in the peer-reviewed Journal of Traditional and Complementary
Medicine.
“Avenova Eye Health Support is another example of NovaBay being
at the forefront of innovation in the eyecare category as we
continue expanding our portfolio of evidence-led, differentiated,
superior-quality and highly effective eyecare products,” he added.
“Consumers and eyecare professionals alike now have another Avenova
product to address the multifactorial and complex condition of dry
eyes.”
The oral supplement is the latest addition to Avenova’s
portfolio of scientifically developed eyecare products targeting
the dry eye market. With the strategic addition of an oral
supplement, the Avenova brand now offers a best-in-class product
for each step of the standard dry-eye treatment regimen: Avenova
antimicrobial lid and lash spray for cleansing, lubricating eye
drops for instant relief, a warm eye compress to soothe, a dietary
supplement of omega-3 oils, and the i-Chek to monitor physical
eyelid health. All Avenova products are available directly to
consumers through online distribution channels such as Amazon and
Avenova.com.
About NovaBay Pharmaceuticals, Inc.
NovaBay Pharmaceuticals, Inc. develops and sells scientifically
created and clinically proven eyecare and skincare products.
DERMAdoctor® offers more than 30 OTC dermatologist-developed
skincare products through the DERMAdoctor website, well-known
traditional and digital beauty retailers, and international
distributors. NovaBay also manufactures and sells effective, yet
gentle and non-irritating wound care products. The PhaseOne® brand
is distributed through commercial partners in the U.S. for
professional use only, and the NeutroPhase® brand is distributed in
China by Pioneer Pharma (Hong Kong) Company Ltd.
NovaBay Pharmaceuticals Forward-Looking Statements
Except for historical information herein, matters set forth in
this press release may be forward looking within the meaning of the
“safe harbor” provisions of the Private Securities Litigation
Reform Act of 1995, including statements about the commercial
progress and future financial performance of NovaBay
Pharmaceuticals, Inc. This release contains forward-looking
statements that are based upon management’s current expectations,
assumptions, estimates, projections and beliefs. These statements
include, but are not limited to, statements regarding our business
strategies, current partnerships, marketing efforts, and any future
revenue that may result from such partnerships and related
marketing initiatives, as well as generally the Company’s expected
future financial results. These statements involve known and
unknown risks, uncertainties and other factors that may cause
actual results or achievements to be materially different and
adverse from those expressed in or implied by the forward-looking
statements. Factors that might cause or contribute to such
differences include, but are not limited to, risks and
uncertainties relating to the size of the potential market for our
products, the possibility that the available market for the
Company’s products will not be as large as expected, the Company’s
products will not be able to penetrate one or more targeted
markets, and revenues will not be sufficient to meet the Company’s
cash needs. Other risks relating to NovaBay’s business, including
risks that could cause results to differ materially from those
projected in the forward-looking statements in this press release,
are detailed in NovaBay’s latest Form 10-Q/K filings and
Registration Statement on Form S-1 filing with the Securities and
Exchange Commission, especially under the heading “Risk Factors.”
The forward-looking statements in this release speak only as of
this date, and NovaBay disclaims any intent or obligation to revise
or update publicly any forward-looking statement except as required
by law.
Socialize and Stay Informed on
NovaBay’s Progress Like us on Facebook Follow us on
Twitter Connect with NovaBay on LinkedIn Visit NovaBay’s
Website
Avenova Purchasing
Information For NovaBay Avenova purchasing information:
Please call 800-890-0329 or email sales@avenova.com Avenova.com
DERMAdoctor Purchasing
Information For DERMAdoctor purchasing information:
Please call 877-337-6237 or email service@dermadoctor.com
DERMAdoctor.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230307005090/en/
NovaBay Contact Justin Hall
Chief Executive Officer and General Counsel 510-899-8800
jhall@novabay.com
Investor Contact LHA
Investor Relations Jody Cain 310-691-7100 jcain@lhai.com
NovaBay Pharmaceuticals (AMEX:NBY)
Historical Stock Chart
From Aug 2024 to Sep 2024
NovaBay Pharmaceuticals (AMEX:NBY)
Historical Stock Chart
From Sep 2023 to Sep 2024